Chandrasekaran, D;
Manchanda, R;
(2018)
Germline & somatic genetic testing in ovarian cancer patients.
BJOG
, 125
(11)
p. 1460.
10.1111/1471-0528.15225.
Preview |
Text
Manchanda_BJOG_Gourley_2017_OG-18871_Commentary_v7.pdf - Accepted Version Download (290kB) | Preview |
Abstract
Genetic testing for germline-BRCA1/BRCA2 mutations in epithelial ovarian cancer (EOC) was commissioned by NHS-England in 2015 following the drop in BRCA-testing threshold to 10% carrier probability. EOC BRCA-carriers can benefit from targeted therapy such as poly-ADP-ribose-polymerase inhibitors (PARP-i) which improve survival in recurrent disease. Additionally, downstream predictive/cascade-testing enables unaffected at-risk mutation carriers to access opportunities of screening and chemoprevention (selective-estrogen-receptor-modulators) for breast cancer (BC), or surgical prevention (risk-reducing mastectomy and/or risk-reducing salpingo-oophorectomy) to reduce their BC and/or ovarian cancer (OC) risks. This article is protected by copyright. All rights reserved.
| Type: | Article |
|---|---|
| Title: | Germline & somatic genetic testing in ovarian cancer patients |
| Location: | England |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1111/1471-0528.15225 |
| Publisher version: | http://dx.doi.org/10.1111/1471-0528.15225 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Inst of Clinical Trials and Methodology |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10046229 |
Archive Staff Only
 |
View Item |
